arXiv:2606.14510v1 Announce Type: new Abstract: Macrocyclic peptides are promising therapeutic candidates for intracellular targets, but their design requires simultaneous control over non-natural monomer chemistry, ring topology, membrane permeability, and target binding. Existing SMILES- or HELM-string generative models either operate in long atom-level sequence spaces or treat monomers as symbolic tokens with limited chemical grounding. We introduce PepALD, an Autoregressive Latent Diffusion (ALD) foundation model for \textit{de novo} macrocyclic peptide generation. The model represents HEL
The convergence of advanced AI generative models and increasing demand for novel therapeutics is enabling new approaches in drug discovery, particularly for complex biological molecules.
This development significantly accelerates the design and optimization of macrocyclic peptides, which are crucial for developing new drugs targeting previously 'undruggable' intracellular targets.
The ability to rapidly generate and optimize macrocyclic peptides using AI shifts drug discovery from laborious experimental screening to more efficient computational design, potentially lowering costs and shortening development timelines.
- · Pharmaceutical R&D
- · Biotechnology companies
- · AI model developers
- · Patients with complex diseases
- · Traditional drug screening methods
- · Small molecule drug developers (relatively)
Increased pipeline of novel macrocyclic peptide candidates entering preclinical development.
Faster and cheaper development of new therapeutic modalities, potentially including personalized medicines.
Revolutions in drug discovery leading to a proliferation of new medicines for currently untreatable conditions, shifting healthcare economics.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG